MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Thermo Fisher Scientific Retained Earnings 2011-2026 | TMO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59.2 B | 53.1 B | 47.4 B | 41.9 B | 35.4 B | 28.1 B | 22.1 B | 18.7 B | 15.9 B | 13.9 B | 12.1 B | 10.4 B | 8.75 B | 7.7 B | 6.72 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 59.2 B | 6.72 B | 25.4 B |
Quarterly Retained Earnings Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 57.4 B | 55.9 B | 54.4 B | 51.4 B | 49.9 B | 48.5 B | 45.9 B | 44.3 B | 43.1 B | 41.9 B | 40.5 B | - | 37.5 B | 35.4 B | 33.9 B | 32.1 B | 30.4 B | 28.1 B | 28.1 B | 28.1 B | 28.1 B | 22.1 B | 22.1 B | 22.1 B | 22.1 B | 18.7 B | 18.7 B | 18.7 B | 18.7 B | 15.9 B | 15.9 B | 15.9 B | 15.9 B | 13.9 B | 13.9 B | 13.9 B | 13.9 B | 12.1 B | 12.1 B | 12.1 B | 12.1 B | 10.4 B | 10.4 B | 10.4 B | 10.4 B | 8.75 B | 8.75 B | 8.75 B | 8.75 B | 7.7 B | 7.7 B | 7.7 B | 7.7 B | 6.72 B | 6.72 B | 6.72 B | 6.72 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 57.4 B | 6.72 B | 22.9 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
-335 M | $ 8.93 | 0.68 % | $ 595 M |  USA |
 |
Brainsway Ltd.
BWAY
|
-77.3 M | $ 13.67 | 0.11 % | $ 99.4 M |  Israel |
 |
Castle Biosciences
CSTL
|
-200 M | $ 25.81 | -0.08 % | $ 717 M | USA |
 |
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
2.43 B | $ 67.83 | 2.24 % | $ 26.5 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
-2.99 B | $ 88.44 | 1.45 % | $ 11.1 B | USA |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 153.93 | 1.29 % | $ 7.63 B | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 17.54 | 1.27 % | $ 935 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | $ 103.98 | 0.12 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
IQVIA Holdings
IQV
|
7.42 B | $ 168.58 | 2.24 % | $ 29 B | USA |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
590 M | $ 15.54 | 3.95 % | $ 470 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
-462 M | $ 16.96 | -1.91 % | $ 2.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 99.21 | 1.63 % | $ 8.18 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
-252 M | $ 2.89 | 1.76 % | $ 93.8 K | USA |
 |
Danaher Corporation
DHR
|
46.9 B | $ 195.14 | 1.96 % | $ 139 B | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Pacific Biosciences of California
PACB
|
-2.7 B | $ 1.42 | 4.41 % | $ 426 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 122.1 | 2.36 % | $ 19.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 198.46 | -0.24 % | $ 22 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.45 B | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
348 M | $ 113.8 | 1.76 % | $ 34.6 B | USA |
 |
BioNano Genomics
BNGO
|
-693 M | $ 1.13 | 1.67 % | $ 1.44 M | USA |
 |
DarioHealth Corp.
DRIO
|
-349 M | $ 9.04 | 7.36 % | $ 256 M | Israel |
 |
NeoGenomics
NEO
|
-434 M | $ 8.31 | 0.85 % | $ 1.06 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.22 | 1.21 % | $ 2 B | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 80.11 | 2.05 % | $ 5.41 B | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
4.6 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 457.31 | 0.81 % | $ 13.2 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
9.24 B | $ 1 218.7 | 1.67 % | $ 25.1 B |  Schweiz |
 |
Celcuity
CELC
|
-272 M | $ 115.13 | 0.2 % | $ 4.54 B | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 17.58 | 1.03 % | $ 393 M | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-1.32 B | $ 47.21 | 4.89 % | $ 2.82 B | USA |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
-1.94 B | $ 199.94 | 1.14 % | $ 19.7 B | USA |